Two of the most effective treatments for relapsing-remitting multiple sclerosis (MS) — Ocrevus (ocrelizumab) and Tysabri (natalizumab) — are essentially matched in their ability to control the disease, a new nationwide study from Denmark suggests. Researchers found no significant difference between the two therapies in preventing relapses, slowing disability progression, or reducing brain lesions. “There is […]
The post Ocrevus and Tysabri appear to work equally well to control relapsing MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com